Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial

The Lancet

Volumn 386, Issue 9999, 2015, Pages 1147-1155

  Leder, Benjamin Z ^a   Tsai, Joy N ^a   Uihlein, Alexander V ^a   Wallace, Paul M ^a   Lee, Hang ^a   Neer, Robert M ^a   Burnett Bowie, Sherri Ann M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY;

AGED; ANEMIA; APPENDICITIS; ARTICLE; ATRIAL FIBRILLATION; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CALCIUM BLOOD LEVEL; CARCINOMA IN SITU; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; DISEASE EXACERBATION; FAINTNESS; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HIP; HIP FRACTURE; HUMAN; HYPERCALCEMIA; INTENTION TO TREAT ANALYSIS; LARYNGITIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MONOTHERAPY; NEPHROLITHIASIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OSSIFICATION; OSTEOLYSIS; OUTCOME ASSESSMENT; PHARYNGITIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SPINE; TREATMENT DURATION; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG SUBSTITUTION; FOLLOW UP; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SINGLE-BLIND METHOD; TERIPARATIDE;

EID: 84942198794     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)61120-5     Document Type: Article

References (36)

1. O Johnell, JA Kanis An estimate of the worldwide prevalence, mortality and disability associated with hip fracture Osteoporos Int 15 2004 897 902
2. O Johnell, JA Kanis An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 2006 1726 1733
3. M Whitaker, J Guo, T Kehoe, G Benson Bisphosphonates for osteoporosis - where do we go from here? N Engl J Med 366 2012 2048 2051
4. DM Black, DC Bauer, AV Schwartz, SR Cummings, CJ Rosen Continuing bisphosphonate treatment for osteoporosis-for whom and for how long? N Engl J Med 366 2012 2051 2053
5. CJ Crandall, SJ Newberry, A Diamant et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review Ann Intern Med 161 2014 711 723
6. BZ Leder, RM Neer, JJ Wyland, HW Lee, SM Burnett-Bowie, JS Finkelstein Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis J Clin Endocrinol Metab 94 2009 2915 2921
7. PD Miller, MA Bolognese, EM Lewiecki et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 2008 222 229
8. BZ Leder, JN Tsai, AV Uihlein et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial J Clin Endocrinol Metab 99 2014 1694 1700
9. JN Tsai, AV Uihlein, H Lee et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial Lancet 382 2013 50 56
10. F Cosman, EF Eriksen, C Recknor et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis J Bone Miner Res 26 2011 503 511
11. DM Black, SL Greenspan, KE Ensrud et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 2003 1207 1215
12. JS Finkelstein, JJ Wyland, H Lee, RM Neer Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis J Clin Endocrinol Metab 95 2010 1838 1845
13. DM Black, M Steinbuch, L Palermo et al. An assessment tool for predicting fracture risk in postmenopausal women Osteoporos Int 12 2001 519 528
14. KE Ensrud, EL Barrett-Connor, A Schwartz et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension J Bone Miner Res 19 2004 1259 1269
15. OH Sorensen, GM Crawford, H Mulder et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 2003 120 126
16. DM Black, IR Reid, S Boonen et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) J Bone Miner Res 27 2012 243 254
17. S Papapoulos, R Chapurlat, C Libanati et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension J Bone Miner Res 27 2012 694 701
18. F Cosman, RA Wermers, C Recknor et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent J Clin Endocrinol Metab 94 2009 3772 3780
19. B Ettinger, J San Martin, G Crans, I Pavo Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 2004 745 751
20. R Eastell, T Nickelsen, F Marin et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS) J Bone Miner Res 24 2009 726 736
21. BM Obermayer-Pietsch, F Marin, EV McCloskey et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment J Bone Miner Res 23 2008 1591 1600
22. S Boonen, F Marin, B Obermayer-Pietsch et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis J Clin Endocrinol Metab 93 2008 852 860
23. PD Miller, PD Delmas, R Lindsay et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate J Clin Endocrinol Metab 93 2008 3785 3793
24. GH Nancollas, R Tang, RJ Phipps et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 2006 617 627
25. DM Black, JP Bilezikian, KE Ensrud et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N Engl J Med 353 2005 555 565
26. RS Rittmaster, M Bolognese, MP Ettinger et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate J Clin Endocrinol Metab 85 2000 2129 2134
27. R Zebaze, E Seeman Cortical bone: a challenging geography J Bone Miner Res 30 2015 24 29
28. Y Bala, R Zebaze, A Ghasem-Zadeh et al. Cortical porosity identifies women with osteopenia at increased risk for forearm fractures J Bone Miner Res 29 2014 1356 1362
29. P Chen, PD Miller, PD Delmas, DA Misurski, JH Krege Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis J Bone Miner Res 21 2006 1785 1790
30. M Austin, YC Yang, E Vittinghoff et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures J Bone Miner Res 27 2012 687 693
31. S Vasikaran, R Eastell, O Bruyere et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards Osteoporos Int 22 2011 391 420
32. E Sornay-Rendu, F Munoz, F Duboeuf, PD Delmas Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study J Bone Miner Res 20 2005 1929 1935
33. C Berger, L Langsetmo, L Joseph et al. Association between change in BMD and fragility fracture in women and men J Bone Miner Res 24 2009 361 370
34. TV Nguyen, JR Center, JA Eisman Femoral neck bone loss predicts fracture risk independent of baseline BMD J Bone Miner Res 20 2005 1195 1201
35. P Garnero, E Sornay-Rendu, B Claustrat, PD Delmas Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study J Bone Miner Res 15 2000 1526 1536
36. J Yates, E Barrett-Connor, S Barlas, YT Chen, PD Miller, ES Siris Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment Obstet Gynecol 103 2004 440 446